Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report


3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report

Johnson & Johnson (NYSE: JNJ) often kicks things off for the healthcare sector with the release of its quarterly earnings, and once again, the largest healthcare company by market cap surpassed Wall Street's loftiest expectations.

For the quarter, J&J, as it's more commonly known, generated $19.65 billion in sales, a 10.3% increase from the prior-year period.  J&J was obviously aided by its acquisition of Actelion, whose specialty lung disease drugs tacked on approximately $670 million in sales during the third quarter. Overall, pharmaceutical growth, sans currency fluctuations, came in at 14.6% during the third quarter, with operating growth of 1.6% for consumer health products and 6.6% for medical devices. It should be noted that the acquisition of Abbott Medical Optics accounted for 5.2% of the 6.6% increase in medical devices, meaning organic growth was a bit tamer. Nonetheless, J&J topped Wall Street's sales expectations by more than $300 million.

Image source: Getty Images.

Continue reading


Source: Fool.com

Johnson & Johnson Stock

€135.12
-0.220%
The price for the Johnson & Johnson stock decreased slightly today. Compared to yesterday there is a change of -€0.300 (-0.220%).
With 42 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 179 € shows a positive potential of 32.47% compared to the current price of 135.12 € for Johnson & Johnson.
Like: 0
JNJ
Share

Comments